Brooklyn ImmunoTherapeutics (NYSE:BTX) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note published on Wednesday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

BTX stock opened at $2.26 on Wednesday. The stock has a market capitalization of $132.95 million, a P/E ratio of -1.00 and a beta of 4.61. The business has a 50-day moving average of $1.96 and a 200-day moving average of $1.80. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC boosted its stake in shares of Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) by 20.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,459,626 shares of the company’s stock after purchasing an additional 243,826 shares during the period. Renaissance Technologies LLC owned 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 26.00% of the company’s stock.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.